Neuren Pharmaceuticals Limited

ASX:NEU 株式レポート

時価総額:AU$2.1b

Neuren Pharmaceuticals 過去の業績

過去 基準チェック /56

Neuren Pharmaceuticalsは、平均年間80.5%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間35.4% 82%収益成長率で 成長しています。 Neuren Pharmaceuticalsの自己資本利益率は53.5%であり、純利益率は60.7%です。

主要情報

80.5%

収益成長率

79.9%

EPS成長率

Pharmaceuticals 業界の成長31.2%
収益成長率82.0%
株主資本利益率53.5%
ネット・マージン60.7%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Nov 11
New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Nov 08
Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Oct 24
Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 29
Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Aug 14
Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

May 31
Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

May 03
Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01
An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05
Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02
Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18
Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02
Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31
Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03
This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07
Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31
Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03
We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06
Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05
We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19
Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

Jan 04
Have Insiders Been Selling Neuren Pharmaceuticals Limited (ASX:NEU) Shares This Year?

収支内訳

Neuren Pharmaceuticals の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

ASX:NEU 収益、費用、利益 ( )AUD Millions
日付収益収益G+A経費研究開発費
30 Jun 2419311750
31 Mar 2421313760
31 Dec 2323215760
30 Sep 2315510650
30 Jun 23785540
31 Mar 23472840
31 Dec 2215030
30 Sep 229-330
30 Jun 223-730
31 Mar 223-730
31 Dec 213-820
30 Sep 212-1020
30 Jun 211-1220
31 Mar 211-1120
31 Dec 201-920
30 Sep 201-820
30 Jun 200-820
31 Mar 200-920
31 Dec 190-1120
30 Sep 197-620
30 Jun 1914-120
31 Mar 1914120
31 Dec 1814320
30 Sep 187320
30 Jun 181310
31 Mar 181320
31 Dec 171320
30 Sep 172-220
30 Jun 173-820
31 Mar 173-1020
31 Dec 163-1220
30 Sep 162-1420
30 Jun 160-1530
31 Mar 161-1430
31 Dec 152-1330
30 Sep 152-1130
30 Jun 153-930
31 Mar 153-930
31 Dec 143-830
30 Sep 143-1020
30 Jun 143-1220
31 Mar 144-1120
31 Dec 135-1020

質の高い収益: NEUは 高品質の収益 を持っています。

利益率の向上: NEUの現在の純利益率 (60.7%)は、昨年(70.3%)よりも低くなっています。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: NEU過去 5 年間で収益を上げており、収益は年間80.5%増加しています。

成長の加速: NEUの過去 1 年間の収益成長率 ( 113.1% ) は、5 年間の平均 ( 年間80.5%を上回っています。

収益対業界: NEUの過去 1 年間の収益成長率 ( 113.1% ) はPharmaceuticals業界46.5%を上回りました。


株主資本利益率

高いROE: NEUの 自己資本利益率 ( 53.5% ) は 傑出している と考えられます。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘